Bleeding risk in East Asian patients with atrial fibrillation: Validation of the DOAC score in a Japanese multicenter registry
The DOAC score proved valuable for long-term bleeding risk assessment in Japanese patients with AF, with enhanced performance through antiplatelet stratification. These findings support its implementation in East Asian populations for individualized clinical decision making.
Authors
- Ryo Nakamaru (ORCID: https://orcid.org/0000-0002-0129-7219)
- Masaki Ieda (ORCID: https://orcid.org/0000-0003-4724-3299)
- Yoshinori Katsumata (ORCID: https://orcid.org/0000-0001-5576-5789)
- Ikuko Ueda
- Shun Kohsaka (ORCID: https://orcid.org/0000-0003-3779-2972)
- Seiji Takatsuki (ORCID: https://orcid.org/0000-0002-0251-5193)
- Kojiro Tanimoto (ORCID: https://orcid.org/0000-0001-6580-2897)
- Takahiko Nishiyama (ORCID: https://orcid.org/0000-0002-2352-5606)
- Takehiro Kimura (ORCID: https://orcid.org/0000-0003-3532-856X)
- Tomohiko Ono
- Yasuyuki Shiraishi (ORCID: https://orcid.org/0000-0001-8788-1186)
Institutions
- Keio University (JP)
- Tokyo Medical Center (JP)
- National Hospital Organization (JP)
- National Hospital Organization Saitama Hospital
Publication Details
- Journal
- Heart Rhythm O2
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1016/j.hroo.2025.06.003
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Bayer Yakuhin
- Japan Society for the Promotion of Science
- Daiichi Sankyo Europe